HOYA’s Visionary Alliance Loyalty Program Exceeds 90-Day Expectations

Customers at all levels are experiencing tiered benefits and rewards

Ophthalmic lens technology leader HOYA Vision Care announced today that the Visionary Alliance, the company’s multi-tiered loyalty program for eye care professionals (ECPs), doubled its 90-day growth expectations following its announcement in May.

Factors for the high enrollment can be attributed to the programs’ uniqueness in the industry. Unlike other programs, the Visionary Alliance is so much more than a glorified discount veiled in points. Customer loyalty is rewarded with escalating value-added services and a truly independent community of peers that ECPs deserve.

“Since launching the Visionary Alliance, ECPs are increasingly choosing HOYA to help their businesses thrive,” said Patrick McCarthy, HOYA Vice President of Sales for Independent Eye Care. “We know our customers and prioritize their needs, and we will continue expanding the value of our program benefits in all tiers.”

The Visionary Alliance offers benefits, tools, and resources that unlock at every level: Insider, Pro, and Elite. At all levels, customers earn and redeem points to exchange for rewards, plus get single sign on access to HOYA Hub and the HOYA Learning Center.

As of October 4, 2021, the program has been enhanced even further to offer growth opportunity baseline-driven add-ons that ECPs can participate in at all levels. This additional benefit offers even more chances to grow their practice and earn rewards on brand and category-specific programs.

Not just a points program, fun and exclusivity are woven into the Visionary Alliance. At Vision Expo West, more than 100 members took advantage of free gondola rides offered by HOYA. The Visionary Alliance also delivered on its promise to host exclusive events for Elite level members across the country. On September 30, HOYA hosted its first global Foresight event live from London. The event featured speakers from Orbis International and the Nomads agency to forecast myopia management and consumer behavior trends.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version